Deals
Mylan to Buy Renaissance Skin Drug Unit for About $1 Billion
This article is for subscribers only.
Mylan NV agreed to buy skin drug assets from Renaissance Acquisition Holdings LLC for about $1 billion to complement its existing products.
Mylan will pay $950 million in cash up front and up to $50 million in future payments for the unit, which sells topical specialty and generic drugs, the companies said Friday in a statement.